Why Attend
Welcome to the 3rd Annual North America Microbiome Congress!
The 3rd Annual North America Microbiome Congress in San Diego, by Kisaco Research, has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require an insight into the latest microbiome research, clinical trials and collaborative partnerships.
With a focus on 5 microbiome niches such as the gut, lung, oral, skin and vaginal- we invite you to join us for 3 days of intense learning, mind-sharing and networking opportunities designed to encourage meaningful connections. In addition, we will be hosting poster sessions for PhD students to provide opportunities for all scientists to learn about state-of-the-art research methods and clinical protocols for conducting microbiome work.
- Meet and learn from industry leaders
- Consider the practical aspects of promoting effective partnerships
- Learn from the latest unpublished data
- Network with top academics and clinicians in the field
Who Will Be There
-
Kisaco Audience Breakdown ChartAcademics30%
-
Kisaco Audience Breakdown ChartInvestors15%
-
Kisaco Audience Breakdown ChartClinicians10%
-
Kisaco Audience Breakdown ChartBiotechs25%
-
Kisaco Audience Breakdown ChartPharmaceutical Companies10%
-
Kisaco Audience Breakdown ChartNutrition Companies10%
-
Academics30%
-
Investors15%
-
Clinicians10%
-
Biotechs25%
-
Pharmaceutical Companies10%
-
Nutrition Companies10%
The Speakers
Stefan Jennewein
Dr. Stefan Jennewein studied Biochemistry, Pharmacology and Organic Chemistry at the Universities of Sussex (Brighton, UK), Zurich (CH), Tübingen (D) and Cambridge (UK), and at the Ludwig-Maximilians-Universität (Munich, D), where he obtained a PhD. He also gained practical experience through his work at Washington State University (Pullman, USA), the company DSM N.V. (Delft, NL), the Technical University of Darmstadt (D), and the Fraunhofer Institute for Molecular Biology and Applied Ecology (Aachen, D) as the Head of the Department of Industrial Biotechnology. Dr. Stefan Jennewein is the Founder & CEO of Jennewein Biotechnologie GmbH
Mary Regan
Mary Regan has a strong clinical background in perinatal nursing, with specific training and expertise in bio informatics. She trained as a certified nurse midwife in the United Kingdom and spent over 19 years working as a perinatal nurse specialist where she gained considerable expertise in pregnancy related health issues. She has been the PI on many State-funded grants and has received NIH funding for a grant focused on women’s decision making about birth (R21 HD059074-01A1) and the vaginal microbiota in preterm birth (R01NR014826-02). The findings from the R21 have been presented internationally and multiple publications have disseminated the findings. The R01 is in its final year and to date over 200 women have been recruited from the birthing population in Baltimore and followed for six month through pregnancy and to the post part period. Dr. Regan works as an Associate Professor in the School of Nursing at the University of Maryland. She serves on the board of Improving Birth.
Jim Weston
Janet Jansson
Janet Jansson is the Division Director of Biological Sciences at the Pacific Northwest National Laboratory (PNNL). She is also PNNL’s sector manager for the U.S. Department of Energy Office of Biological and Environmental Research’s Biological Systems Science Division. Before coming to PNNL (June 2014) she was a senior staff scientist at Lawrence Berkeley National Laboratory (2007-2014) and headed the Ecosystems Biology Program for the Earth Sciences Division at the Berkeley Lab. She also held Adjunct Professor positions at UC Berkeley and the University of Copenhagen, Denmark, from 2012-2014.
Sarkis K. Mazmanian
Sarkis Mazmanian is a medical microbiologist. He has been employed at the California Institute of Technology since 2006, and is currently the Louis & Nelly Soux Professor of Microbiology in the Division of Biology and Biological Engineering. Before his current position, he was associated with the University of Chicago and Harvard Medical School. In 2012, Mazmanian was awarded a MacArthur Fellowship for his pioneering work on the human microbiome. Mazmanian's research investigates the symbiotic relationship between beneficial bacteria and their hosts. In seminal work, Mazmanian discovered the first microbial molecule that has direct beneficial effects on mammals.
Susan Lynch
Research in the Lynch laboratory addresses key areas of human microbiome research:
• Early-life microbiome assembly
• Community perturbation and reassembly
• Relationships between microbiome composition, function and chronic immune activation
• Development of rationally designed novel microbiome-based therapeutics
• The gut-airway axis
Gregory Buck
Josie Ni
Josie was born in Taipei, Taiwan, and grew up in Chicago. She received her undergraduate education from University of California, Berkley, and attended Medical School at Northwestern University. Josie did her Residency at NYU Langone Medical Center in New York, where she was selected as the curriculum Chief Resident, charged with creating a formal program curriculum.
Professor Andreas Bäumler
Professor Michelle McGuire
Shelley McGuire received her BS in biology from the University of Illinois (1986), an MS in nutritional sciences from the University of Illinois (1988), and a PhD in human nutrition from Cornell University (1994). Her research focuses primarily on understanding better how maternal dietary intake and nutritional status influence breast health, milk composition, and duration of postpartum amenorrhea.
David Sela
David Sela is an Assistant Professor in the Department of Food Science. Moreover he holds an adjunct appointment in the Dept. of Microbiology and Dept. of Microbiology and Physiological Systems at the UMass Medical School. Dr. Sela’s research is focused on the mechanisms by which breast milk molecules direct the population structure, and often function, of microbiota that colonize the infant gastrointestinal tract. Dr. Sela joined UMass Amherst after conducting postdoctoral research with David Mills in the Foods for Health Institute at University of California, Davis and David Relman at Stanford University School of Medicine.
Andrew Gewirtz
Andrew Gewirtz, university center professor at Georgia State University, specializes in research on innate immunity, microbiome, intestinal inflammation and obesity/diabetes. Inflammation plays a central role in many disease states, and his goal is to understand the normal mechanisms by which pro-inflammatory signals protect against microbes and discern how they go awry in disease states. His primary area of focus is on the intestinal epithelium.
Gewirtz earned his Ph.D. in Biochemistry from Boston University School of Medicine.
Bruce Taillon
David Kyle
Talk to me about… your research
I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.
Talk to me about…something people may not know about you
I am the named inventor on over 250 patents and was inducted into the US Technology Hall of Fame in 200 for my contributions to Science and Industry. I am passionately engaged in bringing new technologies into commerce to improve the life-long health trajectory of all infants worldwide
Rebecca Santelli
Maria Marco
Professor Marco’s team is investigating the ecology and molecular genetics of beneficial bacteria associated with plant surfaces and mammalian digestive tracts. Organisms of particular interest in the Marco lab are Lactic Acid Bacteria (LAB) found in plant and gut environments. LAB are important for the production of (fermented) food products and specific strains are currently being applied as probiotics to deliver health benefits in the human gut. This lab aims to understand the molecular adaptations and activities of LAB in the context of the indigenous plant and gut microbiota to improve food production and maintain human health.
Dana Graves
In addition to his appointment as a Professor, Department of Periodontics, Dr. Graves is also Vice Dean for Scholarship and Research and Director, Doctor of Science in Dentistry Program at Penn Dental Medicine. He also served as Interim Chair of the Department of Periodontics from 2015 to 2017. His key research interests are in the areas of inflammation and diabetes as they relate to periodontal disease and the loss and repair of connective tissue and bone.
David H. Donabedian
David H. Donabedian, Ph.D., will serve as Chief Executive Officer of Axial and will also serve on its Board. Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.
Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.
He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.
Travis Whitfill
Travis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.
His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States.
Ricardo Teles
Dr. Teles comes to Penn Dental Medicine from the University of North Carolina School of Dentistry, where he served as OraPharma Distinguished Professor in the Department of Periodontology since 2014 and Vice Chair of the Department since 2015. Part of The Forsyth Institute since 2003, Dr. Teles most recently served as Senior Research Investigator (2014-2017) in the Department of Applied Oral Sciences within the Center for Periodontology. From 2010-2014, Dr. Teles also held the appointment of Associate Director of Forsyth’s Center for Clinical and Translational Research and served as the Center’s Director from 2009-2010. Since 2003, he was also a clinical instructor in periodontics at Harvard School of Dental Medicine.
Flavia Teles
Dr. Teles comes to Penn Dental Medicine from the University of North Carolina (UNC) School of Dentistry, where since 2014, she served as Research Associate Professor in the Department of Periodontology, and during that same period, she served as Associate Research Investigator in the Department of Applied Oral Sciences within the Center for Periodontology at The Forsyth Institute, where she had been part of the staff since 2009. Also since 2009, she was an instructor in the Department of Oral Medicine, Infection, and Immunity at Harvard School of Dental Medicine (HSDM), where she was the director of the predoctoral oral microbiology and immunology course. Dr. Teles has also held faculty posts at Mount Ida College, Newton, Mass., and Estácio de Sá University School of Dentistry and Pontificia Universidade Catolica Dental Institute (PUC), both in Rio de Janeiro, Brazil.
Professor Katrine Whiteson
I am a biochemist interested in human associated microbial and viral communities. I use metagenomics, metabolomics, microbial genetics and ecological statistics to answer questions about how microbes and viruses affect human health. I am interested in understanding how individual and persistent human-associated microbial and viral communities affect health. Infection with a bacterial pathogen, vaccination, immune development and even taking a Tylenol does not occur in a vacuum. Dynamic microbial and viral communities constantly inhabit our bodies, encoding the majority of the unique genes that alter these processes. Resident microbial and viral community composition is unique to each human.
Specifically, I am working to understand the role of persistent microbial colonization in triggering inflammatory episodes in Cystic Fibrosis patients. Understanding microbial interactions and changes in microbial physiology that are associated with changes in patient status may lead to the development of biomarkers to diagnose changes in infection earlier and more specifically.
I am also interested in how phage shape dynamic host-associated microbial communities, and in characterizing the function of the 70% of phage encoded genes with no known function.
Iliyan D. Iliev
Iliyan Iliev is an Immunologist and an assistant professor at the Department of Medicine and the Jill Roberts Institute for Research in IBD at Weill Cornell Medical College, New York. He earned his PhD from the European School of Molecular Medicine and the University of Milan, and was previously associated with the Tohoku University in Japan and the Cedars Sinai Medical Center in Los Angeles. Dr. Iliev’s laboratory studies the interaction between commensal microbiota and the immune cells at the mucosal surfaces of the body.
Larry J. Forney
The research done in Dr. Larry Forney’s laboratory centers on the diversity and distribution of prokaryotes. Both field and laboratory studies are done to explore the temporal and spatial patterns of community diversity, as well as factors that influence the dynamics of inter- and intra-species competition. In addition research is done to understand how spatial structure and the resulting environmental gradients influence the tempo and trajectory of adaptive radiations in bacterial species and the maintenance of diversity. Most of these studies are highly interdisciplinary in nature, and done in collaboration with mathematicians, statisticians, computer scientists, geologists, environmental engineers, physicians, and clinical scientists.
David Pride
David Pride’s laboratory focuses on identifying viral members of the human microbiome and in identifying their contributions to human health and disease. He is working on understanding the ecology of viruses and their consequences for our close contacts, characterizing their contributions to community antibiotic resistance, and developing model systems to understand how they respond to perturbations.
Betsy Herold
Betsy Herold, M.D. directs a basic and translational research program, which focuses on the prevention of HIV and HSV and other sexually transmitted infections. Basic research in the lab focuses on defining the cellular signaling pathways that HSV-2 usurps to promote infection. Current work from our laboratory demonstrates that HSV activates calcium (Ca2+), integrin, and phosphorylation signaling pathways and that these pathways play critical roles in the establishment of infection and in cell-to-cell spread of virus. .More recently, the lab has identified a novel cellular protein that plays a key role in the initiation of viral protein expression and could serve as a novel target for prevention strategies. Identification of the viral and cellular factors required for infection has led to development of candidate drugs, which have been formulated for vaginal delivery to prevent both HSV and HIV infection.
Dr. Mark Primental
Dr. Mark Pimentel, serves as a Director of Cedars-sinai Gi Motility Program at Cedars-Sinai Medical Center. Dr. Pimentel has been the Chairman of Clinical Advisory Board at Synthetic Biologics Inc. since April 2014. Dr. Pimentel is an Associate Professor of Medicine at CSMC in Los Angeles, California. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and Internationally.
John Kokai-Kun
Janina Krumbeck
Dr. Krumbeck has received her PhD at the University of Nebraska-Lincoln and has focused her research on gastrointestinal microbiology working on the development of novel synbiotic applications in order to understand microbial ecology and to improve health. At Zymo Research she is part of the microbiomics team which is working towards addressing current challenges in the microbiome research.
Scott Bultman
Vince Wacher
Johan van Hylckama Vlieg
Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for the microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.
Event Partners
Synthetic Biologics
Website: www.syntheticbiologics.com
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead gut microbiome-focused programs poised for Phase 3 development include, SYN-010 a proprietary, modified-release formulation of lovastatin lactone intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004 (ribaxamase), a first-in-class oral enzyme designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and the emergence of antibiotic resistant organisms. The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
Microbiome Labs
Website: https://microbiomelabs.com/
Microbiome Labs was originally established as Physicians Exclusive in 2013 as an organization focused on providing probiotic bacteriotherapy. In the past several years our business model has grown and so has public awareness for gut health issues. Microbiome Labs comes to you as an all inclusive resource center designed to address the needs of physicians and health care practitioners.
Anerobe Systems
Website: https://sites.google.com/site/anaerobesystemspricelist/
Anaerobe Systems produces the only true Pre-Reduced Anaerobically Sterilized (PRAS) plated and tubed culture media in the USA. Founded over 35 years ago, for scientists by scientists, Anaerobe Systems has discovered practical and efficient ways to maximize anaerobic culture techniques. Using a patented procedure, we prepare and package media in an oxygen-free environment from sterilization to packaging. Our product is shipped to you in anaerobic packages. Exposure of specimens to oxygen is eliminated at every step to ensure accurate results.The benefits of such care are greatly reduced time in preparation and handling of cultures and substantially increased recovery of anaerobes.This improved productivity will be visibly apparent within 18 to 24 hours of incubation.
M2P Labs
Website: http://www.m2p-labs.com/
Based in Baesweiler, Germany (near Aachen), the company was founded in November 2005 as a spin-off of RWTH Aachen University. The company focuses on microreaction and automated solutions for screening and bioprocess development. Our commercialized products are the BioLector, the BioLector Pro, and the FlowerPlate, which provide an intelligent micro fermentation platform. This proprietary technology empowers the biotechnology, chemical, and pharmaceutical industries to increase the number and the information content of microbial experiments (aerobic, microaerophilic, and strictly anaerobic). It enables customers to conduct experiments with high efficiency and excellent quality in microscale at low costs. With the RoboLector, the company also enables the
automated fermentation of the whole bioprocess, with the specific integration of the BioLector tool into a liquid handling system.
Evolve Biosystems
Website: https://www.evolvebiosystems.com/
Please visit our website for more information.Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford is a full-service European intellectual property firm at the forefront of a rapidly changing IP landscape.
As a trusted advisor to so many world-class companies and brands, we have been regarded as a pioneer in handling intellectual property for over 200 years. We are known for a consistent ability to anticipate client needs and apply unparalleled expertise to complex challenges.
What sets us apart? We believe it’s our united talents. We join up our knowledge and resources, blending vast experience with infectious enthusiasm, expert knowledge with a constant hunger to learn more and individual skill with great teamwork.
We are unique in our ability to offer a truly integrated service, managing our clients’ intellectual property from inception to commercialisation, enforcement, litigation and defence.
The result is a combined intellectual powerhouse, working closely with our clients to generate the most incisive strategies and arguments.
Clients trust us to get it right.
Jennewein
Website: http://jennewein-biotech.de/
Jennewein Biotechnologie GmbH is a leading company specializing in the production of rare functional monosaccharides.and oligosaccharides for nutritional, pharmaceutical, cosmetic and medical applications. The company produces rare monosaccharides such as L-Fucose and Sialic Acid. It also manufactures an extensive portfolio of HMO’s such as 2‘-Fucosyllactose, 3‘-Fucosyllactose, Lacto-N-tetraose, Lacto-N-neotetraose and acidic HMO’s like 3‘-Sialyllactose and 6‘-Sialyllactose. Jennewein’s human milk oligosaccharides are produced using the latest fermentation technology.This manufacturing process is based on scientific research and ensures a high quality and safety of the product; the oligosaccharides produced in that way are structurally and functionally identical to natural HMO’s. The process can be conducted at reasonable production cost, so that for the first time an HMO can be synthesized in such large amounts that it can be used as supplement in infant food and other food products as for example medical nutrition products or food supplements.Other possible applications are in milk drinks, juices or cereal bars. In the field of R&D the company cooperates with leading German universities and research institutes. Jennewein received in 2015 approval in the US (GRAS) and in 2017 the novel food authorization for 2‘-Fucosyllactose in the European Union. The HMO‘s produced by Jennewein are approved for kosher and halal.The product is marketed under the brand-name Mum’s Sweet Secret.
SynCo Bio Partners
SynCo Bio PartnersB.V. is a world leading cGMP contract manufacturer (CMO) focused to support our customers with clinical and commercial supply of:
- Microbial Products; live microbial therapeutics, vaccines, proteins and polysaccharides
- Aseptic Fill and Lyophilization; of a wide variety of biologics and live microbial therapeutics
Zymo Research
Website: www.zymoresearch.com
Zymo Research has been serving the academic and biopharmaceutical scientific communities by providing DNA and RNA purification products since its inception in 1994. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, and NGS technologies that are high quality and simple to use. The company has been leading the initiative to improve reproducibility and accuracy in the field by developing the first commercially available rigorous standards for microbiome research. The ZymoBIOMICS™ portfolio has been developed as a comprehensive solution for microbiomics and metagenomics from sample collection to analyses.
ubiome
Website: https://ubiome.com/
uBiome’s mission is to explore important research questions about the microbiome and to develop accurate and reliable clinical tests based on the microbiome.
Media Partners
Beneficial Microbes
Website: www.wageningenacademic.com/journals/bm/general-information
Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators
International Journal of Bioinformatics Research and Applications
Website: www.inderscience.com/ijbra
Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.
International Journal of Biotechnology
Website: www.inderscience.com/ijt
IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.
International Journal of Computational Biology and Drug Design
Website: www.inderscience.com/icbdd
IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.
International Journal of Computational Microbiology and Medical Ecology
Website: www.inderscience.com/ijcmme
IJCMME publishes original research contributions on computational microbiology, microbial bioinformatics, and medical ecology. It also covers all aspects of computational microbial ecology. The journal particularly welcomes contributions from studies in the Human Microbiome Project (HMP) and its ramifications in personalised medicine, and considers human microbiome research as a vitally important field of medical ecology, beyond the scope which the eminent microbiologist René Dubos provided regarding the subject several decades ago.
International Journal of Food Safety, Nutrition and Public Health
Website: www.inderscience.com/ijfsnph
IJFSNPH contributes to the improvement of public health through quality research and a better understanding of the science involved in food safety, nutrition and dietetics, food studies, food and restaurant management. To promote better health for all, this initiative aims to broaden the context of public health and health equity, integrate the study of these various disciplines, and foster knowledge transfer on key issues regarding the pivotal role of food safety, nutrition and health equity in influencing health outcomes.
Technology Networks
Website: www.technologynetworks.com
Technology Networks Group is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters. Our global community is made up of over 300,000 researchers and scientific professionals from the life science, drug discovery and analytical arenas. Technology Networks' online communities are dedicated to a wide range of disciplines within the life science, analytical and drug discovery sectors.
Microorganisms Journal
Website: http://www.mdpi.com/journal/microorganisms
Microorganisms (ISSN 2076-2607) is an international, peer-reviewed open access journal which provides an advanced forum for studies related to prokaryotic and eukaryotic microorganisms, viruses and prions. It publishes reviews, research papers and communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. Electronic files and software regarding the full details of the calculation or experimental procedure, if unable to be published in a normal way, can be deposited as supplementary electronic material.
International Journal of Immunology Studies
Website: http://www.inderscience.com/ijis
IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.
Contract Biotechnology
Website: https://www.contract-biotechnology.com/
Contract-Biotechnology.com is a web-based platform for external solutions for R&D projects. We connect researchers and organizations involved in research and development with service and products providers worldwide.
Our mission is to help researchers make breakthrough discoveries, providing them direct access to those contract laboratories that best fit their needs. We help them to find what they need to advance their research. WE MAKE LIFE EASY FOR RESEARCHERS
Biotechgate
Website: http://www.biotechgate.com/web/cms/index.php/start.html
Biotechgate is a global life science data source covering the biotech, pharma and medtech industries. There are currently over 47,000 company profiles available with product pipelines, technologies, in/out licensing opportunities, management details and financial rounds information. Biotechgate is the ideal solution for those looking for partners, clients or funding.
Rapidmicrobiology
Website: http://www.rapidmicrobiology.com/
rapidmicrobiology.com is a well-established on-line resource for microbiologists worldwide, find the right products for your microbiology lab using our specially designed search functions.
Keep up-to-date with the latest microbiology news by getting our free weekly newsletter which includes updates on products, services, webinars, training courses and conferences.
Infectious Diseases Hub
Website: https://www.id-hub.com/
Please visit our website for more information.Medical Microbiology Reports
Website: https://www.scitechnol.com/medical-microbiology-reports.php
Medical Microbiology Reports is a multidisciplinary, peer reviewed, open access journal that reports the advancements in the field of Medical Microbiology including prevention, diagnosis and cure of infectious diseases that may spread due to microbes. The journal also focuses on the widespread dissemination of research related to innovations in the diagnostic tools and therapeutic strategies.
Medical Microbiology Reports journal also provides updated knowledge on topics such as Microbial Pathogens, including Bacteria, Viruses, Fungus, and Parasites, Infectious Diseases – Epidemiology, Immune System: Defense Mechanisms, Immune Responses to Infectious Agents, Genetic Information of Microbes, and Causes & Transmission of Diseases, Disease Diagnosis, Microbial Cultures, Pathogenicity, and Pathogen Interactions.
Journal of Immunological Techniques & Infectious Diseases
Website: https://www.scitechnol.com/infectious-diseases-immunological-techniques.php
Journal of Immunological Techniques and Infectious Diseases (JIDIT) is a scholarly peer-reviewed academic journal that encourages rigorous research that makes a significant contribution in advancing knowledge for immunological application in the treatment of various infectious diseases. JIDIT includes all major themes pertaining to Immunity, Immunization techniques, Vaccination, Epidemology and treatment of infectious diseases.
Scope of the Journal includes:
Epidemology & Pathogenesis of diseases
- Diagnostic Techniques - Advancements
- Immunolgy & Microbiology
- Infectious Diseases & Immune responses
- Vaccination and Development of Vaccines
- Clinical & Experimental Immunology
Journal of Virology & Antiviral Research
Website: https://www.scitechnol.com/virology-antiviral-research.php
Journal of Virology & Antiviral Research publishes original contributions from all sections on the virus, virus-like agents, viral infections of humans, animals, plants and bacteria along with antiviral research studies. It covers the wide range of topics related to newly discovered viruses, studies on viral structure and studies of virus interactions with host cells, organisms and populations.
Kiss The Ground
Website: https://kisstheground.com/
Kiss the Ground is a 501(c)(3) nonprofit on a mission to awaken people to the possibilities of regeneration and inspire participation in this movement through media, communications, education, workshops, immersive programming, and advocacy. Since 2013, Kiss the Ground has created societal awareness around the extraordinary potential of healthy soil, educating and activating millions around regeneration.
You can watch the movie here Watch the Kiss the Ground Movie! - Climate Documentary.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
The Agenda
Download Full Agenda
Young Researcher Inclusion Scheme
This scheme enables you to purchase a single academic rate ticket and a junior member of your lab can attend the conference for free.
To apply, please email [email protected]
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Poster Presentation Submission
If you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress. In order to present a poster, you need to be registered as a delegate. Poster space is assigned on a first come, first served basis. Your presentation will be displayed in a dedicated poster area, while presentation sessions will take place both in the breaks and alongside sessions at prescheduled times.
PLEASE CLICK HERE TO DOWNLOAD THE SUBMISSION FORM
Rising Star Travel Grant
$250 Travel Grants are available for FIVE young researchers (defined as having completed their PhD within the last 5 years). To be considered for one of the Rising Star Travel Grants, you must submit an abstract before 15th December 2017.
PLEASE CLICK HERE TO DOWNLOAD THE SUBMISSION FORM
Commercialisation Surgery
Attendees are invited to pose questions and seek advice from a panel of industry leaders who have been through the commercialisation process.
Innovation Stage
Academics and early stage start-ups are invited to present innovations that they are looking to commercialise. Whether you are looking for investment or just want an expert’s opinion on the next steps in your commercialisation journey, this platform will be valuable for you. This platform allows FOUR presenters to share as much or as little information around their innovation as they feel comfortable, and receive tips and advice from a panel of expert investors, consultants, pharmaceutical companies, lawyers and successful start-ups, as well as input from the audience.
APPLY HERE
Book a Team to Save More!
Industry Rates Only: Team discounts cannot be combined with any other discount or offer
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Payment Terms for the the Microbiome Conference:
- Please note that a $79 processing fee will apply to any invoices requested.
- * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- All discount offers cannot be combined with any other offer.
- Please view our Cancellation Policy.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.